Background: Accurate prediction of SARS-CoV-2 severity remains a challenge. Torque Teno Virus (TTV), recognized as a surrogate marker for cellular immunity in solid organ transplant recipients, holds potential for assessing infection outcomes. Objectives: We investigated whether quantifying TTV in nasopharyngeal samples upon emergency ward (ED) admission could serve as an early predictor of SARS-CoV-2 severity. Study design: Retrospective single-center study in the ED of Saint-Louis Hospital in Paris, France. TTV DNA was quantified in nasopharyngeal swab samples collected for SARS-CoV-2 testing. Results: Among 295 SARS-CoV-2 infected patients, 92 returned home, 160 were admitted to medical wards, and 43 to the intensive care unit. Among 295 SARS-CoV-2 patients, 92 were discharged, 160 hospitalized, and 43 admitted to the intensive care unit (ICU). Elevated TTV loads were observed in ICU patients (Median: 3.02 log copies/mL, interquartile range [IQR]: 2.215-3.825), exceeding those in discharged (2.215, [0; 2.962]) or hospitalized patients (2.24, [0; 3.29]) (p=0.006). Multivariate analysis identified diabetes, obesity, hepatitis, fever, dyspnea, oxygen requirement, and TTV load as predictors of ICU admission. A 2.91 log ₁₀ copies/mL TTV threshold independently predicted ICU admission. Conclusion: Nasopharyngeal TTV quantification in SARS-CoV-2 infected patients is linked to the likelihood of ICU admission and might reflect respiratory immunosuppression.